AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 282 min read$LLY

Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

Eli Lilly's retatrutide outperformed Novo Nordisk's Ozempic in a Phase 3 trial, showing greater blood sugar reduction and weight loss. The highest dose of retatrutide reduced blood sugar by 2.2 percentage points, compared to Ozempic's 1.8 points. Retatrutide also demonstrated significant weight loss, with the highest dose resulting in a 21% reduction, but had higher discontinuation rates due to side effects.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 3:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 4:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The data provides a clear efficacy advantage for Lilly, likely influencing analyst forecasts and investor sentiment.

02

Market read

New pivotal trial data could shift market expectations for obesity/diabetes treatments and affect related stocks.

03

What to watch

Potential safety concerns, manufacturing scale‑up, and payer reimbursement could temper upside.

Relevance 7/10Novelty 9/10Timing: today

Background

The article reports first‑time disclosure of Phase 3 trial results for Eli Lilly's retatrutide versus Novo's Ozempic.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly's Phase 3 trial showed retatrutide lowered A1c by 2.2% and weight by up to 21%, beating Novo's Ozempic.

Expected impact

likely upward pressure as the market prices in potential approval and sales growth

Evidence & confidence

Phase 3 results are a material catalyst; comparable data for a competitor is also disclosed, highlighting Lilly's advantage.

$NVOBearishMedium confidence
Context

Novo Nordisk's Ozempic was outperformed in the same Phase 3 trial, showing lower A1c reduction and weight loss versus Lilly's retatrutide.

Expected impact

potential downside as the market reassesses Novo's competitive position in obesity/diabetes

Evidence & confidence

While the trial is not Novo's own data, the head‑to‑head result highlights a competitive disadvantage.

Market effects

Sector

Strengthens the obesity‑diabetes therapeutic sector for Lilly, may prompt re‑rating of peers.

Regional

U.S. biotech and pharma indices could see modest gains from Lilly's news.

Global

Highlights competitive dynamics between U.S. and European pharma players.

Counterpoint

What could challenge this read

Investors may view the data as early and caution against over‑optimism until FDA filing.

Key entities

  • company
    Eli Lilly

    Pharmaceutical company developing retatrutide.

  • company
    Novo Nordisk

    Pharmaceutical company behind Ozempic.

Read at source← All news

StoryEli Lilly’s retatrutide beats Ozempic in Phase 3 diabetes trial

Also covered by

6 outlets

Related articles

OCT 28
$LLYMed

Eli Lilly Stocks Rise After Retatrutide's Head-to-Head Trial Results

Eli Lilly's shares rose 1.21% to $1,297.37 after its experimental drug retatrutide showed superior weight loss and blood sugar control in a head-to-head trial with Ozempic. The 80-week trial in type 2 diabetes patients showed retatrutide patients lost 47.4 pounds on average, compared to 20.9 pounds with Ozempic. However, more retatrutide patients discontinued treatment due to adverse events. Lilly's market value is $1.22 trillion with a P/E ratio of 44.08, indicating high investor expectations.

finance.yahoo.com2 min
OCT 28
$LLYHigh

Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial

Eli Lilly's retatrutide showed greater reductions in HbA1c and weight loss compared to Novo Nordisk's semaglutide in a phase 3 trial. Retatrutide lowered HbA1c by 2.2 points and achieved 19.5-20.9% weight loss, while semaglutide achieved 1.8 points and 9.4% weight loss. Adverse events led to higher discontinuation rates with retatrutide.

ajmc.com3 min
OCT 28
$NVOMedAI 8/10

Novo Nordisk, Eli Lilly, Pfizer, Roche, Amgen, and Viking Therapeutics are developing new weight-loss drugs

Novo Nordisk, Eli Lilly, Pfizer, Roche, Amgen, and Viking Therapeutics are developing new weight-loss drugs. Novo Nordisk is working on CagriSema and amycretin, while Eli Lilly has Foundayo, retatrutide, and EloraTZP. Roche's enicepatide showed 15.5% weight loss in mid-stage trials, with late-stage tests planned for 2027. Amgen's MariTide is in late-stage trials for obesity and related conditions.

qz.com2 min
OCT 28
$LLYHigh

Lilly’s next-gen drug outperforms Ozempic in weight loss trial

Eli Lilly's experimental drug retatrutide showed greater weight loss and blood sugar control than Novo Nordisk's Ozempic in a late-stage trial. Retatrutide's 9mg and 12mg doses led to an average weight loss of 44.3 and 47.4 pounds, respectively, compared to 20.9 pounds with Ozempic. Lilly plans to seek regulatory approval for retatrutide, which could shift treatment paradigms for type 2 diabetes and obesity if approved.

thenews.com.pk2 min